<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04629508</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 39110-213/LIMBER-213</org_study_id>
    <nct_id>NCT04629508</nct_id>
    <nct_alias>NCT04821791</nct_alias>
  </id_info>
  <brief_title>To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)</brief_title>
  <official_title>A 2-Part, Phase 2, Open-Label Study of the Safety, Tolerability, and Efficacy of Itacitinib Immediate Release in Participants With Primary Myelofibrosis or Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis) Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in&#xD;
      order to select the RP2D for Part 2 of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2021</start_date>
  <completion_date type="Anticipated">July 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 : Treatment Emergent Adverse Events (TEAE'S)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study treatment up to 30 days after last dose of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 : Spleen Volume Reduction by MRI/CT Scan</measure>
    <time_frame>24 weeks</time_frame>
    <description>Defined as the proportion of participants who have a reduction in spleen volume (by imaging) of at least 35 percent when compared with baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 : Spleen Volume Reduction</measure>
    <time_frame>24 weeks</time_frame>
    <description>Defined as the proportion of participants who have a reduction in spleen volume (by imaging) of at least 35% when compared with baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2 : Treatment Emergent Adverse Events (TEAE'S)</measure>
    <time_frame>13 months</time_frame>
    <description>Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study treatment up to 30 days after last dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 : Improvement in Total Symptom Score (TSS)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Defined as the proportion of participants who achieve at least 50% reduction in TSS over the 28 days immediately before the end of Week 24 compared with the 7 days immediately before the initiation of itacitinib IR (baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 : Improvement in quality of life.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Defined as the mean change in the 5 multi-item functional scale scores and the multi-item global health status scale score (EORTC QLQ-C30).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 : Improvement in Patient Global Impression of Change (PGIC)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Defined as percentage of participants who are categorized as improved</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">73</enrollment>
  <condition>Myelofibrosis</condition>
  <condition>Polycythemia Vera</condition>
  <condition>Thrombocythemia</condition>
  <arm_group>
    <arm_group_label>Part 1 : Dose Escalation of itacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be dosed at different dose levels with a maximum of up to 9 participants per dose level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 : Dose Expansion of itacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be dosed at the recommended Phase 2 dose (RP2D) identified in Part 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>itacitinib</intervention_name>
    <description>itacitinb Immediate Release (IR) will be dosed orally twice a day</description>
    <arm_group_label>Part 1 : Dose Escalation of itacitinib</arm_group_label>
    <arm_group_label>Part 2 : Dose Expansion of itacitinib</arm_group_label>
    <other_name>INCB039110</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of primary MF meeting the 2016 WHO criteria for overt PMF or secondary MF&#xD;
             (PPV-MF or PET-MF) meeting the 2008 IWG-MRT criteria.&#xD;
&#xD;
          -  At least Intermediate 1 risk MF according to the DIPSS.&#xD;
&#xD;
          -  Prior treatment with ruxolitinib and/or fedratinib monotherapy&#xD;
&#xD;
          -  Currently receiving ruxolitinib or fedratinib monotherapy for PMF or secondary MF.&#xD;
&#xD;
          -  Splenomegaly defined as palpable spleen at least 5 cm below the left costal margin or&#xD;
             volume ≥ 450 cm3 on imaging assessed during screening.&#xD;
&#xD;
          -  Allogeneic stem cell transplant not planned.&#xD;
&#xD;
          -  Platelet is greater than or equal to 50 × 109/L at screening.&#xD;
&#xD;
          -  Ability to comprehend and willingness to sign a written ICF for the study.&#xD;
&#xD;
          -  Willingness to avoid pregnancy or fathering children.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with a JAK inhibitor other than ruxolitinib or fedratinib&#xD;
&#xD;
          -  Record of ≥ 10% myeloid blasts in the peripheral blood (on peripheral blood smear) or&#xD;
             bone marrow prior to or at the time of screening&#xD;
&#xD;
          -  For participants on ruxolitinib or fedratinib, unable to be tapered from that&#xD;
             treatment over the course of 14 days without corticosteroids, hydroxyurea, or other&#xD;
             agents&#xD;
&#xD;
          -  Treatment with ruxolitinib, fedratinib or other MF-directed therapy (approved or&#xD;
             investigational) within 2 weeks of Day 1&#xD;
&#xD;
          -  Prior splenectomy or splenic irradiation within 6 months before receiving the first&#xD;
             dose of itacitinib&#xD;
&#xD;
          -  Unable or unwilling to undergo serial MRI or CT scans for spleen volume measurement&#xD;
&#xD;
          -  Unable or unwilling to complete MFSAF v4.0 diary on a daily basis during the study&#xD;
&#xD;
          -  ECOG performance status ≥ 3&#xD;
&#xD;
          -  Life expectancy less than 24 weeks&#xD;
&#xD;
          -  Not willing to receive RBC or platelet transfusions&#xD;
&#xD;
          -  Participants with laboratory values at screening outside of protocol defined ranges&#xD;
&#xD;
          -  Significant concurrent, uncontrolled medical condition&#xD;
&#xD;
          -  Participants with impaired cardiac function or clinically significant cardiac disease&#xD;
             unless approved by medical monitor/sponsor&#xD;
&#xD;
          -  History or presence of an abnormal ECG that, in the investigator's opinion, is&#xD;
             clinically meaningful&#xD;
&#xD;
          -  Chronic or current active infectious disease requiring systemic antibiotics,&#xD;
             antifungal, or antiviral treatment.&#xD;
&#xD;
          -  Evidence of HBV or HCV infection or risk of reactivation&#xD;
&#xD;
          -  Known HIV infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>eumedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rcca Md, Llc</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midamerica Cancer Care</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Jersey Hematology Oncology Associates Llc</name>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <zip>08724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246-2092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Renovatio Clinical Consultants, LLC</name>
      <address>
        <city>Spring</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Interne 1 - Hematologie Mit Stammzelltransplantation, Hemostaseologie Und Medizinische Onkologie Ord</name>
      <address>
        <city>Linz</city>
        <zip>70376</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ DELTA</name>
      <address>
        <city>Roeselare</city>
        <zip>08800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu Mont Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>05530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Halle (Saale)</name>
      <address>
        <city>Halle (saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aou San Giovanni Di Dio E Ruggi</name>
      <address>
        <city>Salerno</city>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Treviso Hospital</name>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari I Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46000</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelofibrosis</keyword>
  <keyword>Post-PV Myelofibrosis</keyword>
  <keyword>Post-ET Myelofibrosis</keyword>
  <keyword>LIMBER</keyword>
  <keyword>LIMBER-213</keyword>
  <keyword>MF</keyword>
  <keyword>Myeloproliferative Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.</ipd_time_frame>
    <ipd_access_criteria>Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.incyte.com/our-company/compliance-and-transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

